WS
TXMD icon

Wedbush Securities’s TherapeuticsMD TXMD Stock Holding History

Wedbush Securities’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-360
Closed -$28K – 974
2020
Q3 		$28K Sell
360
-120
-25% -$9.56K ﹤0.01% 914
2020
Q2 		$30K Buy
+480
New +$27.9K ﹤0.01% 931

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Wedbush Securities's TXMD Position: Q4 2020 in Review

Wedbush Securities sold out of TherapeuticsMD (TXMD) in Q4 2020, closing a stake of 360 shares — an estimated $28K sold.

Wedbush Securities first reported a position in TXMD in Q2 2020 and held it in 2 quarters. The position peaked at $30K in Q2 2020. 159 funds tracked by Wall St. Rank hold TXMD as of Q4 2020.

  • Wedbush Securities reported no remaining TherapeuticsMD position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 360 TherapeuticsMD shares in Q4 2020, an estimated $28K.
  • Wedbush Securities first reported a position in TherapeuticsMD in Q2 2020 and held it in 2 quarters.
  • Wedbush Securities's TherapeuticsMD position peaked at $30K in Q2 2020.
  • 159 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.